vs
Side-by-side financial comparison of Hologic (HOLX) and Cloudflare, Inc. (NET). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $614.5M, roughly 1.7× Cloudflare, Inc.). Hologic runs the higher net margin — 17.1% vs -2.0%, a 19.1% gap on every dollar of revenue. On growth, Cloudflare, Inc. posted the faster year-over-year revenue change (33.6% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $105.2M). Over the past eight quarters, Cloudflare, Inc.'s revenue compounded faster (27.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Cloudflare, Inc. is an American technology company headquartered in San Francisco, California, that provides a range of internet services, including content delivery network (CDN) services, cloud cybersecurity, DDoS mitigation, and ICANN-accredited domain registration. The company's services act primarily as a reverse proxy between website visitors and a customer's hosting provider, improving performance and protecting against malicious traffic.
HOLX vs NET — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $614.5M |
| Net Profit | $179.1M | $-12.1M |
| Gross Margin | 56.0% | 73.6% |
| Operating Margin | 22.6% | -8.0% |
| Net Margin | 17.1% | -2.0% |
| Revenue YoY | 2.5% | 33.6% |
| Net Profit YoY | -10.9% | 6.0% |
| EPS (diluted) | $0.79 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $614.5M | ||
| Q3 25 | $1.0B | $562.0M | ||
| Q2 25 | $1.0B | $512.3M | ||
| Q1 25 | $1.0B | $479.1M | ||
| Q4 24 | $1.0B | $459.9M | ||
| Q3 24 | $988.0M | $430.1M | ||
| Q2 24 | $1.0B | $401.0M | ||
| Q1 24 | $1.0B | $378.6M |
| Q4 25 | $179.1M | $-12.1M | ||
| Q3 25 | $187.2M | $-1.3M | ||
| Q2 25 | $194.9M | $-50.4M | ||
| Q1 25 | $-17.4M | $-38.5M | ||
| Q4 24 | $201.0M | $-12.8M | ||
| Q3 24 | $178.6M | $-15.3M | ||
| Q2 24 | $194.5M | $-15.1M | ||
| Q1 24 | $169.9M | $-35.5M |
| Q4 25 | 56.0% | 73.6% | ||
| Q3 25 | 55.6% | 74.0% | ||
| Q2 25 | 56.3% | 74.9% | ||
| Q1 25 | 37.5% | 75.9% | ||
| Q4 24 | 56.8% | 76.4% | ||
| Q3 24 | 56.4% | 77.7% | ||
| Q2 24 | 55.4% | 77.8% | ||
| Q1 24 | 53.3% | 77.5% |
| Q4 25 | 22.6% | -8.0% | ||
| Q3 25 | 22.6% | -6.7% | ||
| Q2 25 | 24.9% | -13.1% | ||
| Q1 25 | -0.7% | -11.1% | ||
| Q4 24 | 22.5% | -7.5% | ||
| Q3 24 | 23.3% | -7.2% | ||
| Q2 24 | 24.1% | -8.7% | ||
| Q1 24 | 20.7% | -14.4% |
| Q4 25 | 17.1% | -2.0% | ||
| Q3 25 | 17.8% | -0.2% | ||
| Q2 25 | 19.0% | -9.8% | ||
| Q1 25 | -1.7% | -8.0% | ||
| Q4 24 | 19.7% | -2.8% | ||
| Q3 24 | 18.1% | -3.6% | ||
| Q2 24 | 19.2% | -3.8% | ||
| Q1 24 | 16.7% | -9.4% |
| Q4 25 | $0.79 | $-0.03 | ||
| Q3 25 | $0.84 | $0.00 | ||
| Q2 25 | $0.86 | $-0.15 | ||
| Q1 25 | $-0.08 | $-0.11 | ||
| Q4 24 | $0.87 | $-0.05 | ||
| Q3 24 | $0.75 | $-0.04 | ||
| Q2 24 | $0.82 | $-0.04 | ||
| Q1 24 | $0.72 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $943.5M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $1.5B |
| Total Assets | $9.2B | $6.0B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $943.5M | ||
| Q3 25 | $2.2B | $1.1B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $1.6B | $204.5M | ||
| Q4 24 | $2.0B | $147.7M | ||
| Q3 24 | $2.3B | $182.9M | ||
| Q2 24 | $2.4B | $157.0M | ||
| Q1 24 | $2.2B | $254.4M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $1.5B | ||
| Q3 25 | $5.0B | $1.3B | ||
| Q2 25 | $4.8B | $1.2B | ||
| Q1 25 | $4.6B | $1.4B | ||
| Q4 24 | $4.8B | $1.0B | ||
| Q3 24 | $5.1B | $973.1M | ||
| Q2 24 | $5.0B | $881.5M | ||
| Q1 24 | $4.8B | $797.2M |
| Q4 25 | $9.2B | $6.0B | ||
| Q3 25 | $9.0B | $5.8B | ||
| Q2 25 | $8.8B | $5.6B | ||
| Q1 25 | $8.5B | $3.7B | ||
| Q4 24 | $8.7B | $3.3B | ||
| Q3 24 | $9.2B | $3.1B | ||
| Q2 24 | $8.9B | $2.9B | ||
| Q1 24 | $8.7B | $2.8B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $190.4M |
| Free Cash FlowOCF − Capex | $215.2M | $105.2M |
| FCF MarginFCF / Revenue | 20.5% | 17.1% |
| Capex IntensityCapex / Revenue | 1.4% | 13.9% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $287.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $190.4M | ||
| Q3 25 | $355.1M | $167.1M | ||
| Q2 25 | $343.3M | $99.8M | ||
| Q1 25 | $169.4M | $145.8M | ||
| Q4 24 | $189.3M | $127.3M | ||
| Q3 24 | $367.0M | $104.7M | ||
| Q2 24 | $405.8M | $74.8M | ||
| Q1 24 | $292.4M | $73.6M |
| Q4 25 | $215.2M | $105.2M | ||
| Q3 25 | $341.4M | $82.5M | ||
| Q2 25 | $330.5M | $39.9M | ||
| Q1 25 | $153.9M | $59.9M | ||
| Q4 24 | $172.5M | $54.2M | ||
| Q3 24 | $350.6M | $54.5M | ||
| Q2 24 | $385.3M | $45.2M | ||
| Q1 24 | $279.6M | $41.5M |
| Q4 25 | 20.5% | 17.1% | ||
| Q3 25 | 32.5% | 14.7% | ||
| Q2 25 | 32.3% | 7.8% | ||
| Q1 25 | 15.3% | 12.5% | ||
| Q4 24 | 16.9% | 11.8% | ||
| Q3 24 | 35.5% | 12.7% | ||
| Q2 24 | 38.1% | 11.3% | ||
| Q1 24 | 27.5% | 11.0% |
| Q4 25 | 1.4% | 13.9% | ||
| Q3 25 | 1.3% | 15.1% | ||
| Q2 25 | 1.3% | 11.7% | ||
| Q1 25 | 1.5% | 17.9% | ||
| Q4 24 | 1.6% | 15.9% | ||
| Q3 24 | 1.7% | 11.7% | ||
| Q2 24 | 2.0% | 7.4% | ||
| Q1 24 | 1.3% | 8.5% |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
NET
| Sales Channel Directly To Consumer | $438.5M | 71% |
| Sales Channel Through Intermediary | $176.0M | 29% |
